EU backs Glaxo's breast cancer drug with warnings

LONDON, April 24 (Reuters) - European drug regulators said on Thursday they recommended approval of GlaxoSmithKline Plc's (GSK.L: Quote, Profile, Research) new breast cancer pill Tykerb, or Tyverb, but with additional warnings about potential liver toxicity.

The European Medicines Agency's expert committee was asked to look again at the product by the European Commission last month after clinical data showed that hepatotoxicity -- predominantly elevated liver enzymes -- could occur during treatment with the drug. (Reporting by Ben Hirschler)